Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Nick van Dijk, Alberto Gil-Jimenez, Karīna Siliņa, Kees Hendricksen, Laura A. Smit, Jeantine M. de Feijter, Maurits L. van Montfoort, C. van Rooijen, Dennis Peters, Annegien Broeks, Henk G. van der Poel, Annemarie Bruining, Yoni Lubeck, Karolina Sikorska, Thierry N. Boellaard, Pia Kvistborg, Daniël J. Vis, Erik Hooijberg, Ton N. Schumacher, Maries van den Broek, Lodewyk F.A. Wessels, Christian U. Blank, Bas W. van Rhijn, Michiel S. van der Heijden
Topics & Concepts
NivolumabIpilimumabMedicineClinical endpointInternal medicineOncologyAdverse effectClinical trialCancerImmunotherapyProgressive diseaseGastroenterologySurgeryUrologyDiseaseBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersUrinary and Genital Oncology Studies